Radiopharm Theranostics (ASX:RAD) Receives Approval to Conduct Phase 1 Trial for RAD 202

December 20, 2024 01:27 PM AEDT | By Sonal Goyal

Radiopharm Theranostics (ASX:RAD) Receives Approval to Conduct Phase 1 Trial for RAD 202 — Image source: Company update

Recent News

IGF 2024 Concludes 19th Edition, Calling for Enhanced Digital Cooperat...

The Art of Lightness: ASUS to Unveil World's Lightest Copilot+ PC

YolTech Therapeutics Announces Successful Completion of Dose Escalatio...

Samsung Press Conference at CES 2025 'AI for All: Everyday, Everywhere...

Highlights

The Belberry Human Research Ethics Committee (HREC) granted approval for the Phase 1 trial of ¹⁷⁷Lu-RAD202 targeting HER2-expressing metastatic solid tumors.

The dose-escalation study plans to recruit participants across Australia with the support of GenesisCare CRO.

RAD shares jumped 16.67% to AU$0.024 in morning trade on 20 December 2024.

Shares of Radiopharm Theranostics (ASX:RAD) surged 16.67% to AU$0.024 per share in morning trade on 20 December 2024, following an update on the Phase 1 therapeutic trial of ¹⁷⁷Lu-RAD202. The company’s ¹⁷⁷Lu-labelled RAD 202 has secured approval from Belberry Human Research Ethics Committee (HREC) to commence Phase 1 therapeutic clinical trial for HER2-expressing solid tumors treatment.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Full Name

Mobile

By submitting your details above and clicking on the 'Download Report' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.